Study to describe the processing of ropivacaine in the body when injected in the knee for pain treatment in total knee arthroplasty.
Completed
- Conditions
- Total Knee ArthroplastyRopivacainetourniquetPharmacokinetic profileTotale knieprotheseropivacainebloedleegtebandfarmacokinetisch profiel
- Registration Number
- NL-OMON24359
- Lead Sponsor
- Sint Maartenskliniek Nijmegen
- Brief Summary
https://rapm.bmj.com/content/43/7/699.long
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
age 50-80 years
-ASA physical health classification I ¨C II
Exclusion Criteria
-Placement of a surgical drain
-Contra-indications for spinal anesthesia
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -Mean total and unbound maximum serum concentration of ropivacaine (Cmax and Cumax)<br /><br>-Mean time to total and unbound maximum serum concentration of ropivacaine (Tmax an Tumax)
- Secondary Outcome Measures
Name Time Method not applicable